TY - JOUR
T1 - Formulation of chrysin loaded nanostructured lipid carriers using Box Behnken design, its characterization and antibacterial evaluation alone and in presence of probiotics co-loaded in gel
AU - Parveen, Shaik Rahana
AU - Wadhwa, Sheetu
AU - Babu, Molakpogu Ravindra
AU - Vishwas, Sukriti
AU - Corrie, Leander
AU - Awasthi, Ankit
AU - Khan, Farhan R.
AU - Al-Bazi, Maha M.
AU - Alharthi, Nahed S.
AU - Alotaibi, Faisal
AU - Gupta, Gaurav
AU - Pandey, Narendra Kumar
AU - Kumar, Bimlesh
AU - Kumbhar, Popat
AU - Disouza, John
AU - Gulati, Monica
AU - Neelamraju, Jayanthi
AU - Madempudi, Ratna Sudha
AU - Dua, Kamal
AU - Singh, Sachin Kumar
N1 - Publisher Copyright:
© 2023 Elsevier B.V.
PY - 2023/6
Y1 - 2023/6
N2 - The present study deciphers formulation, optimization and characterization of chrysin nanostructured lipid carriers with probiotics (PB) loaded gel (Chrysin (CS)- Nanostructured lipid carriers (NLCs) + PB loaded gel) for topical application. Hot homogenization-probe sonication method was used to formulate NLCs. Formulation parameters were optimized using Box Behnken Design. The optimized formulation was characterized for particle size (PS), zeta potential (ZP), % entrapment efficiency (%EE), % drug loading (%DL). The optimized values were found to be 199.99 mg, 33.92 mg, 700 mg and 376.86 mg of solid lipid, liquid lipid, surfactant and co-surfactant respectively. The PS, ZP, % EE and % DL of optimized CS-NLCs + PB loaded gel were found to be 66.45 ± 5.62 nm, −22 ± 5.21 mV, 97.25 ± 0.15 and 82.3 ± 0.104, respectively. Transmission electron microscopic images revealed that NLCs loaded with CS were spherical in shape. The in vitro diffusion studies revealed that 98 ± 0.06% of CS got released from CS-NLCs + PB loaded gel at the end of 48 h. For initial 8h, release of CS was about 6-fold higher in case of CS-NLCs + PB loaded gel than that of naive CS gel and thereafter the release got reduced, which indicated the sustained release of CS from NLCs. The zone of inhibition of CS-NLCs + PB loaded gel was 0.5-fold, 0.2-fold and 0.54-fold higher than naive PB gel alone, naïve CS gel alone and CS-PB gel combination, respectively. It indicated significantly higher antibacterial activity of CS–NLCs + PB loaded gel as that of any other treatment group.
AB - The present study deciphers formulation, optimization and characterization of chrysin nanostructured lipid carriers with probiotics (PB) loaded gel (Chrysin (CS)- Nanostructured lipid carriers (NLCs) + PB loaded gel) for topical application. Hot homogenization-probe sonication method was used to formulate NLCs. Formulation parameters were optimized using Box Behnken Design. The optimized formulation was characterized for particle size (PS), zeta potential (ZP), % entrapment efficiency (%EE), % drug loading (%DL). The optimized values were found to be 199.99 mg, 33.92 mg, 700 mg and 376.86 mg of solid lipid, liquid lipid, surfactant and co-surfactant respectively. The PS, ZP, % EE and % DL of optimized CS-NLCs + PB loaded gel were found to be 66.45 ± 5.62 nm, −22 ± 5.21 mV, 97.25 ± 0.15 and 82.3 ± 0.104, respectively. Transmission electron microscopic images revealed that NLCs loaded with CS were spherical in shape. The in vitro diffusion studies revealed that 98 ± 0.06% of CS got released from CS-NLCs + PB loaded gel at the end of 48 h. For initial 8h, release of CS was about 6-fold higher in case of CS-NLCs + PB loaded gel than that of naive CS gel and thereafter the release got reduced, which indicated the sustained release of CS from NLCs. The zone of inhibition of CS-NLCs + PB loaded gel was 0.5-fold, 0.2-fold and 0.54-fold higher than naive PB gel alone, naïve CS gel alone and CS-PB gel combination, respectively. It indicated significantly higher antibacterial activity of CS–NLCs + PB loaded gel as that of any other treatment group.
KW - Antibacterial activity
KW - Chrysin
KW - Nanostructured lipid carriers
KW - Probiotic
UR - http://www.scopus.com/inward/record.url?scp=85152446424&partnerID=8YFLogxK
U2 - 10.1016/j.jddst.2023.104411
DO - 10.1016/j.jddst.2023.104411
M3 - Article
AN - SCOPUS:85152446424
SN - 1773-2247
VL - 84
JO - Journal of Drug Delivery Science and Technology
JF - Journal of Drug Delivery Science and Technology
M1 - 104411
ER -